Profile data is unavailable for this security.
About the company
Beta Drugs Limited is an India-based oncology medicine manufacturing company. The Company specializes in the intricate field of complex chemical synthesis for anti-cancer bulk drugs and finished dosages. The Company operates through one segment, Pharmaceuticals. Its product category includes cosmeceutical products and oncology products. The cosmeceutical products include La’Thrix, BACINOX, URTICALM, HUMIDA, NUSPLASH, UVIREX, ADVIBE, SENSIBAR, and RECAPRO. The oncology products include Temozad(Temozolomide), ADVIN(Vinorelbine), ADSIDE(Etoposide), ADRIB(Doxorubicin), ADCOV(Leucovorin calcium), ADPLATIN(Oxaliplatin), INOTAD(Irinotecan), ADCIST(Cisplatin), ADCARB(Carboplatin), ERLOTAD(Erlotinib), ADOXI(Docetaxel), AMGICIN(Gemcitabine), ADPAXIL(Paclitaxel), ADMIDE(Bicalutamide), and others. The Company's subsidiaries include Adley Lab Limited and Adley Formulations Private Limited.
- Revenue in INR (TTM)3.86bn
- Net income in INR464.68m
- Incorporated2005
- Employees399.00
- LocationBeta Drugs LtdSco 184, Sector 5, PanchkulaPANCHKULA 134114IndiaIND
- Phone+91 17 225854813
- Websitehttps://betadrugslimited.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wanbury Ltd | 6.58bn | 646.86m | 9.13bn | 1.38k | 13.66 | -- | 11.53 | 1.39 | 19.13 | 19.13 | 194.16 | -- | -- | -- | -- | 4,758,967.00 | -- | 8.87 | -- | 101.40 | 55.07 | 41.82 | 9.84 | 5.62 | -- | 2.97 | -- | -- | 4.15 | 10.29 | -45.44 | -13.88 | 44.32 | -- |
| Sigachi Industries Ltd | 5.06bn | -550.46m | 9.46bn | 1.10k | -- | 1.86 | -- | 1.87 | -1.46 | -1.46 | 13.20 | 13.29 | 0.6316 | 2.40 | 2.80 | 4,624,222.00 | -6.70 | 12.29 | -9.77 | 16.21 | 52.83 | 51.93 | -10.62 | 14.80 | 1.27 | 5.53 | 0.2436 | 4.23 | 22.38 | 28.55 | 21.66 | 27.91 | 48.87 | -- |
| Venus Remedies Ltd | 7.00bn | 762.95m | 10.10bn | 1.30k | 13.23 | -- | 10.11 | 1.44 | 57.10 | 57.10 | 523.77 | -- | -- | -- | -- | 5,391,957.00 | -- | 6.67 | -- | 8.08 | 47.02 | 37.62 | 10.90 | 6.87 | -- | 1,849.19 | -- | -- | 7.72 | 13.81 | 59.05 | -- | 18.36 | -- |
| Sakar Healthcare Ltd | 2.31bn | 252.21m | 10.45bn | 342.00 | 41.02 | -- | 21.63 | 4.53 | 11.45 | 11.45 | 104.95 | -- | -- | -- | -- | 6,750,901.00 | -- | 4.73 | -- | 5.64 | 52.54 | 45.55 | 10.92 | 9.87 | -- | 3.66 | -- | -- | 15.80 | 16.44 | 49.96 | 12.71 | 19.34 | -- |
| Lincoln Pharmaceuticals Ltd | 6.32bn | 800.04m | 10.59bn | 1.85k | 13.24 | 1.48 | 11.32 | 1.68 | 39.95 | 39.95 | 315.68 | 357.35 | 0.7736 | 3.56 | 3.63 | 3,411,578.00 | 9.79 | 13.22 | 11.45 | 15.46 | 53.35 | 50.82 | 12.66 | 14.56 | 4.01 | 56.06 | 0.00009 | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| IND Swift Laboratories Ltd | 9.64bn | 2.75bn | 10.86bn | 1.25k | 3.48 | -- | 3.38 | 1.13 | 38.28 | 38.28 | 122.91 | -- | -- | -- | -- | 7,738,014.00 | -- | 8.65 | -- | 10.59 | 51.55 | 40.96 | 28.56 | 14.35 | -- | -3.35 | -- | 0.00 | -56.15 | -6.35 | -40.50 | -- | 41.97 | -- |
| Bajaj Healthcare Ltd | 6.12bn | 523.16m | 11.85bn | 904.00 | 23.23 | -- | 14.85 | 1.93 | 16.15 | 15.36 | 188.83 | -- | -- | -- | -- | 6,774,850.00 | -- | 7.07 | -- | 13.07 | 46.31 | 37.17 | 8.54 | 8.22 | -- | 2.92 | -- | 5.83 | 14.61 | 5.76 | 399.64 | 11.21 | -12.65 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.82bn | 409.03m | 12.25bn | 1.40k | 30.16 | -- | 24.34 | 4.35 | 6.07 | 6.07 | 41.76 | -- | -- | -- | -- | 2,012,738.00 | -- | 14.71 | -- | 17.26 | 63.66 | 60.59 | 14.53 | 12.54 | -- | 44.64 | -- | 39.88 | 28.76 | 11.13 | 146.45 | 47.72 | -28.44 | 65.72 |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 13.02bn | 562.00 | 40.60 | -- | 21.83 | 4.14 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Syncom Formulations (India) Ltd | 5.15bn | 630.52m | 13.39bn | 554.00 | 20.64 | 3.54 | 19.59 | 2.60 | 0.69 | 0.69 | 5.56 | 4.03 | 1.24 | 8.89 | 5.41 | 9,296,547.00 | 15.22 | 8.56 | 17.65 | 11.58 | 36.52 | 34.81 | 12.24 | 10.15 | 4.24 | 73.92 | 0.0018 | -- | 76.55 | 17.74 | 95.28 | 28.24 | 41.62 | -- |
| Beta Drugs Ltd | 3.86bn | 464.68m | 13.66bn | 399.00 | 19.41 | 6.18 | 22.31 | 3.54 | 69.72 | 65.19 | 509.33 | 218.94 | 0.986 | 3.64 | 3.48 | 9,665,303.00 | 11.88 | 15.08 | 16.29 | 21.53 | 39.79 | 40.30 | 12.05 | 12.72 | 2.45 | 5.13 | 0.3974 | 0.00 | 22.54 | 31.89 | 28.96 | 37.92 | 19.23 | -- |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 13.81bn | 456.00 | 39.03 | -- | 25.94 | 3.09 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Windlas Biotech Ltd | 8.68bn | 667.47m | 16.69bn | 1.35k | 25.17 | -- | 17.06 | 1.92 | 31.46 | 31.46 | 409.16 | -- | -- | -- | -- | 6,450,929.00 | -- | 8.65 | -- | 11.81 | 38.34 | 34.09 | 7.69 | 7.70 | -- | 15.80 | -- | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
